Cargando…

Intestinal fatty acid‐binding protein is a biomarker for diagnosis of biliary tract infection

BACKGROUND AND AIM: Biliary tract infection (BTI) is an inflammatory disease and commonly associated with bacteremia. Delays in diagnosis or treatment of BTI cause high morbidity and mortality. However, an early diagnosis depends on appropriate clinical investigations. Appropriate biomarkers are urg...

Descripción completa

Detalles Bibliográficos
Autores principales: Weng, Yu‐Chieh, Chen, Wei‐Ting, Lee, Jung‐Chieh, Huang, Yung‐Ning, Yang, Chih‐Kai, Hsieh, Hui‐Shan, Chang, Chih‐Jung, Lu, Yang‐Bor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485399/
https://www.ncbi.nlm.nih.gov/pubmed/34622002
http://dx.doi.org/10.1002/jgh3.12644
_version_ 1784577531428470784
author Weng, Yu‐Chieh
Chen, Wei‐Ting
Lee, Jung‐Chieh
Huang, Yung‐Ning
Yang, Chih‐Kai
Hsieh, Hui‐Shan
Chang, Chih‐Jung
Lu, Yang‐Bor
author_facet Weng, Yu‐Chieh
Chen, Wei‐Ting
Lee, Jung‐Chieh
Huang, Yung‐Ning
Yang, Chih‐Kai
Hsieh, Hui‐Shan
Chang, Chih‐Jung
Lu, Yang‐Bor
author_sort Weng, Yu‐Chieh
collection PubMed
description BACKGROUND AND AIM: Biliary tract infection (BTI) is an inflammatory disease and commonly associated with bacteremia. Delays in diagnosis or treatment of BTI cause high morbidity and mortality. However, an early diagnosis depends on appropriate clinical investigations. Appropriate biomarkers are urgently needed to improve the BTI diagnostic rate. We hypothesized that intestinal fatty acid‐binding protein (I‐FABP) might be a potential biomarker for BTI diagnosis. METHODS: We examined data from subjects aged ≥18 years diagnosed with BTI, including cholangitis and cholecystitis, whose blood samples were adequate for I‐FABP and zonulin assessment. We also collected blood samples from healthy volunteers as the control group. We excluded subjects in both groups who received steroids, antibiotics, or probiotics within 1 month before hospital admission (BTI cohort) or participation in this research (controls). The main study endpoint was to compare the diagnostic ability of I‐FABP to detect BTI in comparison with high‐sensitivity C‐reactive protein (hs‐CRP) and zonulin. RESULTS: The study collected the data of 51 patients with BTI and 35 healthy subjects. The receiver operating characteristic (ROC) area under the curve (AUC) for I‐FABP was 0.884 (95% confidence interval [CI]: 0.814–0.954), numerically higher than that for hs‐CRP (0.880; 0.785–0.976) and zonulin (0.570; 0.444–0.697). We estimated that the optimal cutoff value of I‐FABP was 2.1 ng/mL (sensitivity: 0.804; specificity: 0.829) for the diagnosis of BTI. CONCLUSIONS: In summary, this study suggests that I‐FABP may be a potential alternative biomarker to hs‐CRP for diagnosing BTI. Further research should verify the use of I‐FABP as a marker for BTI diagnosis, but also for other inflammatory diseases.
format Online
Article
Text
id pubmed-8485399
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wiley Publishing Asia Pty Ltd
record_format MEDLINE/PubMed
spelling pubmed-84853992021-10-06 Intestinal fatty acid‐binding protein is a biomarker for diagnosis of biliary tract infection Weng, Yu‐Chieh Chen, Wei‐Ting Lee, Jung‐Chieh Huang, Yung‐Ning Yang, Chih‐Kai Hsieh, Hui‐Shan Chang, Chih‐Jung Lu, Yang‐Bor JGH Open Original Articles BACKGROUND AND AIM: Biliary tract infection (BTI) is an inflammatory disease and commonly associated with bacteremia. Delays in diagnosis or treatment of BTI cause high morbidity and mortality. However, an early diagnosis depends on appropriate clinical investigations. Appropriate biomarkers are urgently needed to improve the BTI diagnostic rate. We hypothesized that intestinal fatty acid‐binding protein (I‐FABP) might be a potential biomarker for BTI diagnosis. METHODS: We examined data from subjects aged ≥18 years diagnosed with BTI, including cholangitis and cholecystitis, whose blood samples were adequate for I‐FABP and zonulin assessment. We also collected blood samples from healthy volunteers as the control group. We excluded subjects in both groups who received steroids, antibiotics, or probiotics within 1 month before hospital admission (BTI cohort) or participation in this research (controls). The main study endpoint was to compare the diagnostic ability of I‐FABP to detect BTI in comparison with high‐sensitivity C‐reactive protein (hs‐CRP) and zonulin. RESULTS: The study collected the data of 51 patients with BTI and 35 healthy subjects. The receiver operating characteristic (ROC) area under the curve (AUC) for I‐FABP was 0.884 (95% confidence interval [CI]: 0.814–0.954), numerically higher than that for hs‐CRP (0.880; 0.785–0.976) and zonulin (0.570; 0.444–0.697). We estimated that the optimal cutoff value of I‐FABP was 2.1 ng/mL (sensitivity: 0.804; specificity: 0.829) for the diagnosis of BTI. CONCLUSIONS: In summary, this study suggests that I‐FABP may be a potential alternative biomarker to hs‐CRP for diagnosing BTI. Further research should verify the use of I‐FABP as a marker for BTI diagnosis, but also for other inflammatory diseases. Wiley Publishing Asia Pty Ltd 2021-08-20 /pmc/articles/PMC8485399/ /pubmed/34622002 http://dx.doi.org/10.1002/jgh3.12644 Text en © 2021 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Weng, Yu‐Chieh
Chen, Wei‐Ting
Lee, Jung‐Chieh
Huang, Yung‐Ning
Yang, Chih‐Kai
Hsieh, Hui‐Shan
Chang, Chih‐Jung
Lu, Yang‐Bor
Intestinal fatty acid‐binding protein is a biomarker for diagnosis of biliary tract infection
title Intestinal fatty acid‐binding protein is a biomarker for diagnosis of biliary tract infection
title_full Intestinal fatty acid‐binding protein is a biomarker for diagnosis of biliary tract infection
title_fullStr Intestinal fatty acid‐binding protein is a biomarker for diagnosis of biliary tract infection
title_full_unstemmed Intestinal fatty acid‐binding protein is a biomarker for diagnosis of biliary tract infection
title_short Intestinal fatty acid‐binding protein is a biomarker for diagnosis of biliary tract infection
title_sort intestinal fatty acid‐binding protein is a biomarker for diagnosis of biliary tract infection
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485399/
https://www.ncbi.nlm.nih.gov/pubmed/34622002
http://dx.doi.org/10.1002/jgh3.12644
work_keys_str_mv AT wengyuchieh intestinalfattyacidbindingproteinisabiomarkerfordiagnosisofbiliarytractinfection
AT chenweiting intestinalfattyacidbindingproteinisabiomarkerfordiagnosisofbiliarytractinfection
AT leejungchieh intestinalfattyacidbindingproteinisabiomarkerfordiagnosisofbiliarytractinfection
AT huangyungning intestinalfattyacidbindingproteinisabiomarkerfordiagnosisofbiliarytractinfection
AT yangchihkai intestinalfattyacidbindingproteinisabiomarkerfordiagnosisofbiliarytractinfection
AT hsiehhuishan intestinalfattyacidbindingproteinisabiomarkerfordiagnosisofbiliarytractinfection
AT changchihjung intestinalfattyacidbindingproteinisabiomarkerfordiagnosisofbiliarytractinfection
AT luyangbor intestinalfattyacidbindingproteinisabiomarkerfordiagnosisofbiliarytractinfection